IL269250A - High affinity mage-a1-specific tcrs and uses thereof - Google Patents

High affinity mage-a1-specific tcrs and uses thereof

Info

Publication number
IL269250A
IL269250A IL26925019A IL26925019A IL269250A IL 269250 A IL269250 A IL 269250A IL 26925019 A IL26925019 A IL 26925019A IL 26925019 A IL26925019 A IL 26925019A IL 269250 A IL269250 A IL 269250A
Authority
IL
Israel
Prior art keywords
mage
high affinity
specific tcrs
tcrs
specific
Prior art date
Application number
IL26925019A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of IL269250A publication Critical patent/IL269250A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
IL26925019A 2017-03-15 2019-09-10 High affinity mage-a1-specific tcrs and uses thereof IL269250A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471956P 2017-03-15 2017-03-15
PCT/US2018/022759 WO2018170338A2 (en) 2017-03-15 2018-03-15 High affinity mage-a1-specific tcrs and uses thereof

Publications (1)

Publication Number Publication Date
IL269250A true IL269250A (en) 2019-11-28

Family

ID=63523985

Family Applications (1)

Application Number Title Priority Date Filing Date
IL26925019A IL269250A (en) 2017-03-15 2019-09-10 High affinity mage-a1-specific tcrs and uses thereof

Country Status (13)

Country Link
US (2) US11034748B2 (enExample)
EP (1) EP3595708A4 (enExample)
JP (2) JP7037577B2 (enExample)
KR (1) KR102375033B1 (enExample)
CN (1) CN110582299A (enExample)
AU (1) AU2018234830B2 (enExample)
BR (1) BR112019018863A8 (enExample)
CA (1) CA3055983A1 (enExample)
EA (1) EA201992131A1 (enExample)
IL (1) IL269250A (enExample)
MX (1) MX2019010972A (enExample)
SG (1) SG11201908527SA (enExample)
WO (1) WO2018170338A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018138838A (ru) 2016-04-08 2020-05-14 Адаптимьюн Лимитед Т-клеточные рецепторы
KR102375218B1 (ko) 2016-12-08 2022-03-17 이매틱스 바이오테크놀로지스 게엠베하 T 세포 수용체 및 이를 사용하는 면역 요법
DE102016123847B3 (de) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
CA3055983A1 (en) * 2017-03-15 2018-09-20 Fred Hutchinson Cancer Research Center High affinity mage-a1-specific tcrs and uses thereof
AU2019256536B2 (en) 2018-04-19 2025-09-18 Baylor College Of Medicine Reprogramming CD4 T cells into cytotoxic CD8 cells by forced expression of CD8αβ and Class 1 restricted T cell receptors
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
TWI850360B (zh) * 2019-04-04 2024-08-01 德商梅迪基因免疫治療公司 黑色素瘤相關抗原１（ｍａｇｅａ１）特異性ｔ細胞受體及其用途
SG11202111865UA (en) * 2019-05-01 2021-11-29 Pact Pharma Inc Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
BR112022014623A2 (pt) 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
CN111320703A (zh) * 2020-03-11 2020-06-23 北京双赢科创生物科技有限公司 靶向cd22的嵌合抗原受体及其应用
CN111499763A (zh) * 2020-03-31 2020-08-07 江苏省省级机关医院 一种靶向mage-a1的特异性全人源嵌合抗原受体及其应用
AU2021270378A1 (en) * 2020-05-13 2022-12-15 Adaptimmune Limited Method of treatment of cancer or tumour
CN112194719A (zh) * 2020-09-01 2021-01-08 中日友好医院(中日友好临床医学研究所) Crt抗原和mage-a1抗原的制备及其应用
TW202222841A (zh) 2020-10-06 2022-06-16 福瑞德哈金森腫瘤研究中心 用於治療表現mage-a1之疾病的組成物及方法
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022132836A2 (en) 2020-12-14 2022-06-23 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
WO2022221478A1 (en) * 2021-04-14 2022-10-20 Tscan Therapeutics, Inc. Binding proteins recognizing ha-2 antigen and uses thereof
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
WO2023083864A1 (en) 2021-11-09 2023-05-19 T-Knife Gmbh Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences Inc Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
CN116948011A (zh) * 2022-04-27 2023-10-27 恒瑞源正(广州)生物科技有限公司 Mage-a1特异性t细胞受体及其用途
EP4534554A1 (en) * 2022-06-01 2025-04-09 Corregene Biotechnology Co., Ltd. Mage-a1 specific tcr and use thereof
NL2032130B1 (en) * 2022-06-10 2023-12-18 Academisch Ziekenhuis Leiden T cell receptors directed against melanoma-associated antigen and uses thereof
JP2025522762A (ja) 2022-07-01 2025-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
AU2024259556A1 (en) 2023-04-21 2025-10-23 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
TW202519517A (zh) 2023-07-26 2025-05-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025146286A1 (en) * 2024-01-04 2025-07-10 Immunoscape Pte. Ltd. Human t cell receptors and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596536B1 (en) * 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
WO2003078619A1 (en) 2002-03-15 2003-09-25 Cellectis Hybrid and single chain meganucleases and use thereof
JP2006518372A (ja) 2003-01-28 2006-08-10 セレクティス 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
WO2006076678A2 (en) 2005-01-13 2006-07-20 The Johns Hopkins University Prostate stem cell antigen vaccines and uses thereof
GB0511124D0 (en) * 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
US8021867B2 (en) 2005-10-18 2011-09-20 Duke University Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
US20080064631A1 (en) * 2006-01-13 2008-03-13 Jeffrey Molldrem T-cell receptors for use in diagnosis and therapy of cancers and autoimmune disease
US8871211B2 (en) * 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
WO2008108257A1 (ja) * 2007-03-05 2008-09-12 International Institute Of Cancer Immunology, Inc. 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用
KR101319499B1 (ko) 2008-02-22 2013-10-17 엘지디스플레이 주식회사 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법
PL3006459T3 (pl) 2008-08-26 2022-01-17 City Of Hope Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
US8785601B2 (en) * 2009-01-28 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
US9228007B1 (en) * 2010-03-11 2016-01-05 The Regents Of The University Of California Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
US9586997B2 (en) * 2010-09-20 2017-03-07 Biontech Cell & Gene Therapies Gmbh Antigen-specific T cell receptors and T cell epitopes
WO2012054825A1 (en) 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
JP6066909B2 (ja) * 2011-06-28 2017-01-25 株式会社癌免疫研究所 ペプチド癌抗原特異的ｔ細胞のレセプター遺伝子
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
CN102295702B (zh) * 2011-08-26 2014-01-29 中国科学院微生物研究所 一种针对t细胞受体可变区特异性单抗的制备方法
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
WO2013176772A1 (en) 2012-05-25 2013-11-28 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
MX380109B (es) 2012-08-20 2025-03-12 Fred Hutchinson Cancer Center Star Metodo y composiciones para inmunoterapia celular.
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
DK2921557T3 (en) 2012-12-12 2016-11-07 Broad Inst Inc Design of systems, methods and optimized sequence manipulation guide compositions
WO2014100483A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. Anti-human b7-h4 antibodies and their uses
DK2951202T3 (da) * 2013-01-29 2020-07-13 Max Delbrueck Centrum Fuer Molekulare Medizin Mdc Berlin Buch Mage-a1-genkendende bindingsmolekyler med høj aviditet
JP6464140B2 (ja) * 2013-03-13 2019-02-06 ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． 腫瘍抗原を直接認識するために組換えｔ細胞レセプターを使用するための組成物及び方法
WO2015066262A1 (en) 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
EP3071695A2 (en) 2013-11-18 2016-09-28 Crispr Therapeutics AG Crispr-cas system materials and methods
BR112016011567A2 (pt) * 2013-11-22 2017-10-24 Hutchinson Fred Cancer Res receptores de célula t humana de alta afinidade geneticamente modificados.
PT3514172T (pt) * 2014-04-01 2020-04-21 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Imunorrecetores específicos de claudina-6 e epítopos de células t
US10202640B2 (en) 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing
EP2944652A1 (en) * 2014-05-13 2015-11-18 Technische Universität München Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
ES2841274T3 (es) * 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res Inmunoterapia con células T específica para WT-1
AR101848A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos de anti-b7-h4 e inmunoconjugados
WO2016040900A1 (en) * 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
BR112017006825A2 (pt) 2014-10-03 2017-12-12 Dana Farber Cancer Inst Inc anticorpos contra receptor do fator de necrose tumoral induzido por glicocorticoides (gitr) e seus métodos de utilização
PL3258951T3 (pl) 2015-02-19 2020-07-27 Compugen Ltd. Przeciwciała anty-pvrig i sposoby ich zastosowania
CA2984234C (en) * 2015-05-01 2023-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
CN106188274A (zh) * 2015-05-06 2016-12-07 广州市香雪制药股份有限公司 识别rhamm抗原短肽的t细胞受体
JP6568239B2 (ja) * 2015-06-01 2019-08-28 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体ライブラリ
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CN105316362B (zh) * 2015-08-19 2020-03-17 暨南大学 一种Dual-RMCE介导的TCR基因置换系统及其方法
CN106749620B (zh) * 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
KR102436129B1 (ko) * 2016-06-17 2022-08-26 메디진 이뮤노테라피스 게엠바하 T 세포 수용체 및 이의 용도
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
DE102016123847B3 (de) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
CA3055983A1 (en) * 2017-03-15 2018-09-20 Fred Hutchinson Cancer Research Center High affinity mage-a1-specific tcrs and uses thereof

Also Published As

Publication number Publication date
BR112019018863A2 (pt) 2020-04-14
CN110582299A (zh) 2019-12-17
MX2019010972A (es) 2019-12-02
JP7037577B2 (ja) 2022-03-16
BR112019018863A8 (pt) 2023-05-02
EA201992131A1 (ru) 2020-02-06
EP3595708A2 (en) 2020-01-22
US20200017568A1 (en) 2020-01-16
SG11201908527SA (en) 2019-10-30
AU2018234830A1 (en) 2019-09-26
US20210355189A1 (en) 2021-11-18
CA3055983A1 (en) 2018-09-20
JP2020509767A (ja) 2020-04-02
KR20190129082A (ko) 2019-11-19
WO2018170338A3 (en) 2019-11-21
JP2021090462A (ja) 2021-06-17
EP3595708A4 (en) 2020-12-16
US11034748B2 (en) 2021-06-15
WO2018170338A2 (en) 2018-09-20
KR102375033B1 (ko) 2022-03-15
AU2018234830B2 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
IL269250A (en) High affinity mage-a1-specific tcrs and uses thereof
IL293377A (en) Hsd17b13 variants and uses thereof
EP3724208A4 (en) COMPOSITIONS CONSISTING OF CIRCULAR POLYRIBONUCLEOTIDES AND THEIR USES
IL265449A (en) Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
EP3707248A4 (en) MODIFIED IMMUNE CELLS AND THEIR USES
DK3630232T3 (da) Autoinjektor med variabel stempelkraft
IL268593A (en) Polypeptide variants and uses thereof
HUE071316T2 (hu) Fotovoltaikus berendezés és annak alkalmazása
HUE049851T2 (hu) Bilincset és érintetlenségjelzõ burkolatot tartalmazó szerkezet
EP3411412A4 (en) FIT-IMMUNOGLOBULIN TECHNOLOGY AND USES THEREOF
HUE046621T2 (hu) Promóter szekvencia és alkalmazásai
DK2961835T3 (da) Ny bakteriophag og antibakteriel sammensætning omfattende samme
EP3511407A4 (en) CHRISTENSENELLA INTESTINIHOMINIS AND APPLICATION THEREOF
EP3893945A4 (en) CROMOGLYC ESTERS AND THEIR USES
EP3415518A4 (en) MACROCYCLUS AND COMPOSITION THEREOF
EP3538113A4 (en) HIGH AFFINITY MERKEL CELL POLYOMAVIRUS T ANTIGEN SPECIFIC TCRs AND THEIR USES
EP3665191A4 (en) SPECIFIC BRAF TCRs AND RELATED USES
EP3730565A4 (en) MULTI-LAYER STRUCTURE AND ITS USES
EP3478770A4 (en) SILICONE RUBBER COMPOSITION AND COMPOSITE OBTAINED FROM THE SILICONE RUBBER COMPOSITION
HUE054822T2 (hu) Triciklusos vegyület és ennek alkalmazásai
HUE035778T2 (hu) Polimixin származék és alkalmazásai
EP3530984A4 (en) LINEAR ACTUATOR HAVING A FREE FALL FUNCTION
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
EP3424705A4 (en) LAMINATE AND APPLICATION THEREOF
EP3466269A4 (en) COMPOSITION CONTAINING CAFFEINE AND CYCLOALANYLALANINE